Antisense modulation of IL7R splicing to control sIL7R expression in human CD4+T cells
Open Access
- 25 May 2022
- journal article
- research article
- Published by Cold Spring Harbor Laboratory in RNA
- Vol. 28 (8), 1058-1073
- https://doi.org/10.1261/rna.079137.122
Abstract
The interleukin 7 receptor (IL7R) is strongly associated with increased risk to develop multiple sclerosis (MS), an autoimmune disease of the central nervous system, and this association is likely driven by up-regulation of the soluble isoform of IL7R (sIL7R). Expression of sIL7R is determined by exclusion of the alternative exon 6 from IL7R transcripts, and our previous work revealed that the MS risk allele of the SNP rs6897932 within this exon enhances the expression of sIL7R by promoting exclusion of exon 6. sIL7R potentiates the activity of IL7, leading to enhanced expansion of T cells and increased disability in the experimental autoimmune encephalomyelitis (EAE) murine model of MS. This role in modulating T cell-driven immunity positions sIL7R as an attractive therapeutic target whose expression could be reduced for treatment of MS or increased for treatment of cancers. In this study, we identified novel antisense oligonucleotides (ASOs) that effectively control the inclusion (anti-sIL7R ASOs) or exclusion (pro-sIL7R ASOs) of this exon in a dose-dependent fashion. These ASOs provided excellent control of exon 6 splicing and sIL7R secretion in human primary CD4+ T cells. Supporting their potential for therapeutic targeting, we showed that lead anti-sIL7R ASOs correct the enhanced exon 6 exclusion imposed by the MS risk allele of rs6897932, whereas lead pro-sIL7R ASOs phenocopy it. The data presented here form the foundation for future preclinical studies that will test the therapeutic potential of these ASOs in MS and immuno-oncology.Keywords
Funding Information
- University of Texas Medical Branch
- a Technology Commercialization Plan grant from the University of Texas Medical Branch
- NIH (R41-AI141323, R41-AI149920)
This publication has 77 references indexed in Scilit:
- Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunityProceedings of the National Academy of Sciences of the United States of America, 2013
- Cleavage and polyadenylation specificity factor 1 (CPSF1) regulates alternative splicing of interleukin 7 receptor (IL7R) exon 6RNA, 2012
- IL-7 receptor α blockade, an off-switch for autoreactive T cellsProceedings of the National Academy of Sciences of the United States of America, 2012
- IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasisSeminars in Immunology, 2012
- Anti–IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell functionProceedings of the National Academy of Sciences of the United States of America, 2012
- IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cellsProceedings of the National Academy of Sciences of the United States of America, 2012
- Interleukin-7 receptor blockade suppresses adaptive and innate inflammatory responses in experimental colitisJournal of Inflammation, 2012
- Systemic Autoimmunity and Lymphoproliferation Are Associated with Excess IL-7 and Inhibited by IL-7Rα BlockadePLOS ONE, 2011
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studyThe Lancet, 2011
- Role of CXCR3 Ligands in IL-7/IL-7Rα-Fc–Mediated Antitumor Activity in Lung CancerClinical Cancer Research, 2011